메뉴 건너뛰기




Volumn 373, Issue 3, 2015, Pages 274-276

Another beginning for cystic fibrosis therapy

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

EID: 84937053668     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1504059     Document Type: Editorial
Times cited : (18)

References (10)
  • 1
    • 33847053615 scopus 로고    scopus 로고
    • Cystic fibrosis transmembrane regulator protein mutations: 'Class' opportunity for novel drug innovation
    • MacDonald KD, McKenzie KR, Zeitlin PL Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs 2007; 9: 1-10.
    • (2007) Paediatr Drugs , vol.9 , pp. 1-10
    • MacDonald, K.D.1    McKenzie, K.R.2    Zeitlin, P.L.3
  • 2
    • 80455162465 scopus 로고    scopus 로고
    • A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
    • Ramsey BW, Davies J, McElvaney N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-72.
    • (2011) N Engl J Med , vol.365 , pp. 1663-1672
    • Ramsey, B.W.1    Davies, J.2    McElvaney, N.G.3
  • 3
    • 81755163563 scopus 로고    scopus 로고
    • Correction of the F508del-CFTR protein processing defect in vitro by the in-vestigational drug VX-809
    • Van Goor F., Hadida S, Grootenhuis P.D., et al. Correction of the F508del-CFTR protein processing defect in vitro by the in-vestigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108: 18843-8.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 18843-18848
    • Van Goor, F.1    Hadida, S.2    Grootenhuis, P.D.3
  • 4
    • 84926090443 scopus 로고    scopus 로고
    • Combined effects of VX-770 and VX-809 on several functional Abnormalities of F508del-CFTR channels
    • Kopeikin Z, Yuksek Z, Yang H.Y., Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros 2014; 13: 508-14.
    • (2014) J Cyst Fibros , vol.13 , pp. 508-514
    • Kopeikin, Z.1    Yuksek, Z.2    Yang, H.Y.3    Bompadre, S.G.4
  • 5
    • 84937035647 scopus 로고    scopus 로고
    • Lumacaftorivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR
    • Wainwright CE, Elborn JS, Ramsey B.W., et al. Lumacaftorivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220-31.
    • (2015) N Engl J Med , vol.373 , pp. 220-231
    • Wainwright, C.E.1    Elborn, J.S.2    Ramsey, B.W.3
  • 6
    • 0028129568 scopus 로고
    • Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
    • Fuchs HJ, Borowitz DS, Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
    • (1994) N Engl J Med , vol.331 , pp. 637-642
    • Fuchs, H.J.1    Borowitz, D.S.2    Christiansen, D.H.3
  • 7
    • 0033531143 scopus 로고    scopus 로고
    • Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
    • Ramsey BW, Pepe MS, Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.
    • (1999) N Engl J Med , vol.340 , pp. 23-30
    • Ramsey, B.W.1    Pepe, M.S.2    Quan, J.M.3
  • 8
    • 84919770501 scopus 로고    scopus 로고
    • Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein
    • Robertson SM, Luo X, Dubey N., et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 2015; 55: 56-62.
    • (2015) J Clin Pharmacol , vol.55 , pp. 56-62
    • Robertson, S.M.1    Luo, X.2    Dubey, N.3
  • 9
    • 84907211027 scopus 로고    scopus 로고
    • Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
    • Veit G, Avramescu RG, Perdomo D, et al Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 2014; 6: 46ra97.
    • (2014) Sci Transl Med , vol.6 , pp. 46ra97
    • Veit, G.1    Avramescu, R.G.2    Perdomo, D.3
  • 10
    • 84907223425 scopus 로고    scopus 로고
    • Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
    • Cholon DM, Quinney NL, Fulcher M.L., et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 2014; 6: 46ra96.
    • (2014) Sci Transl Med , vol.6 , pp. 46ra96
    • Cholon, D.M.1    Quinney, N.L.2    Fulcher, M.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.